

BRIEF COMMUNICATION

Red hair, *MC1R* variants, and risk for Parkinson's disease – a meta-analysisXiqun Chen^{1,2}, Danielle Feng¹, Michael A. Schwarzschild¹ & Xiang Gao³¹MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, 02129 Massachusetts²Shanghai 10th Hospital, Tongji University School of Medicine, Shanghai, China³Department of Nutritional Sciences, The Pennsylvania State University, University Park, 16802 Pennsylvania**Correspondence**

Xiqun Chen, Department of Neurology, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02119. Tel: 617-643-7215; Fax: 617-724-1480; E-mail: xchen17@mgh.harvard.edu and

Xiang Gao, Department of Nutritional Sciences, the Pennsylvania State University, University Park, PA 16802. Tel: 814-867-5959; Fax: 814-863-6103; E-mail: xxg14@psu.edu

Funding information

The authors are supported by the Michael J. Fox Foundation (9908 to X. C.), National Institute of Health (1R21NS090246-01A1 to X. C., 5R21NS087235-02 to X. G.), National Natural Science Foundation of China (81471293 to X.C.).

Received: 27 September 2016; Revised: 17 November 2016; Accepted: 18 November 2016

Annals of Clinical and Translational Neurology 2017; 4(3): 212–216

doi: 10.1002/acn3.381

Introduction

Although there is a general inverse association between cancer and Parkinson's disease (PD),^{1,2} the one exception of melanoma has been well-documented, not only in patients themselves but also in their relatives.^{3,4} Little is known regarding mechanisms underlying the reciprocally increased risk of the two disparate diseases. However, efforts have been made in recent years to investigate potential genetic intersections and common pathological pathways.^{2,5} Melanoma is strongly tied to red hair/fair skin, a phenotype of loss-of-function of the melanocortin-1 receptor gene (*MC1R*), the key

Abstract

Several studies have been conducted with mixed results since our initial report of increased Parkinson's disease risk in individuals with red hair and/or red hair-associated p.R151C variant of the *MC1R* gene, both of which confer high melanoma risk. We performed a meta-analysis of six publications on red hair, *MC1R*, and Parkinson's disease. We found that red hair (pooled odds ratios = 1.68, 95% confidence intervals: 1.07, 2.64) and p.R151C (pooled odds ratios = 1.10, 95% confidence intervals: 1.00, 1.21), but not p.R160W, were associated with greater risk for Parkinson's disease. Our results support potential roles of pigmentation and its key regulator *MC1R* in the pathogenesis of Parkinson's disease.

pigmentation gene.⁶ Our initial investigation based on more than 120,000 US men and women demonstrated that red hair color and red hair-associated *MC1R* p.R151C polymorphism (rs1805007) were associated with higher risk of PD.⁵ *MC1R* variants have since garnered considerable interest and debate over their significance in the PD and melanoma association.^{7–11} In a case-control study based on 870 PD cases in Spain, another red hair-associated *MC1R* variant p.R160W (rs1805008) was found to be associated with higher PD risk.⁸ However, other epidemiological studies on this topic did not support an *MC1R*-PD link.^{9–11} In this report, we searched all literature indexed in PubMed and performed meta-

analyses of studies that examined the association between red hair color, *MC1R* p.R151C or p.R160W, two most studied *MC1R* loss-of-function polymorphisms, and PD risk.

Methods

Literature search and data extraction

We searched all published literature in MEDLINE via PubMed up to July 2016 that reported PD associations with hair color, *MC1R* variants, and amino acid changes. For inclusion in *MC1R* variant analyses, all studies must have reported the specific variants or amino acid changes of interest, and the relative risks (RRs) or odds ratios (ORs). We extracted information on year of study, study type and population, cases and controls population size, country origin, focus of study, PD ascertainment method, variant of interest, lower and upper confidence intervals

(CIs), minor allele frequency (MAF) in PD patients and controls, model or test type, and adjustment covariates.

Statistical analyses

We used Q statistic to examine heterogeneity among the studies and the significance level was set at 0.1. We used fixed-effects models to calculate the summary ORs as no significant heterogeneity was identified (P -heterogeneity ≥ 0.2 for all analyses). We did not adjust for multiple comparison because the current analyses were hypothesis-driven. Publication bias was examined with the Begg and Egger tests.

Results

We identified six publications based on eight study cohorts in total from 2009 to 2016, all with study focus on hair color or *MC1R* p.R151C or p.R160W polymorphisms (Table 1).^{5,7–11} PD cases were of US, French/

Table 1. Characteristics of publications included in meta-analysis of hair color, *MC1R* p.R151C, and p.R160W polymorphisms and risk for PD.

Publication (reference#)	Study type	Study/population	Study size	Exposures	Effect estimate RR or OR (95% CI)	Adjustment
Gao ⁵	Cohort nested case-control	HPFS NHS	Cohort study: 132,302 participants and 539 PD cases Case-control study: PD cases: 272 Controls: 1185	Red versus black hair color p.R151C	RR = 1.93 (1.08, 3.43) OR = 1.37 (0.99, 1.89)	smoking, ethnicity, BMI, nonsteroid antiinflammatory drug, alcohol intake, caffeine intake, lactose
Dong ⁷	Nested case-control	PAGE within NIH-AARP Diet and Health Cohort	PD cases: 808 Controls: 1623	Red versus black hair color p.R160W	OR = 1.36 (0.66, 2.79) OR = 1.14 (0.89, 1.44)	age, sex, smoking status, and caffeine intake
	Case-control	IPDGC	PD cases: 5333 Controls: 12019	p.R151C p.R160W	OR = 1.06 (0.94, 1.09) OR = 0.98 (0.89, 1.07)	
Tell-Marti ⁸	Case-control	Parkinson's Disease and Movement Disorders Unit of Hospital Clinic of Barcelona Spanish Mediterranean Caucasians	PD cases: 870 Controls: 736	p.R151C p.R160W	OR = 1.25 (0.80, 1.95) OR = 2.10 (1.18, 3.73)	age, sex
Lubbe ⁹	Cohort	"An additional large cohort collected through IPDGC" ⁹	PD cases: 5944 Controls: 4642	p.R160W	OR = 1.01 (0.90, 1.13)	sex, population stratification
Gan-Or ¹⁰	Case-control	Columbia University Medical Center, New York	PD cases: 539 Controls: 265	p.R151C p.R160W	OR = 0.77 (0.48, 1.23) OR = 0.92 (0.53, 1.57)	age, sex
	Case-control	Montreal Neurological Institute European ancestry	PD cases: 551 Controls: 956	p.R151C p.R160W	OR = 0.92 (0.57, 1.47) OR = 1.13 (0.68, 1.90)	
Lorenzo-Betancor ¹¹	Case-control	Mayo Clinic Non-Hispanic Caucasian	PD cases: 889 Controls: 940	p.R151C p.R160W	OR = 1.27 ($P = 0.068$) OR = 1.06 ($P = 0.62$)	

RR, the relative risks; OR, odds ratios; CI, confidence intervals; HPFS, the health professionals follow-up study; NHS, the nurses' health study; PD, Parkinson's disease; BMI, body mass index; PAGE, Parkinson's genes and environment; AARP, the American Association of Retired Persons; IPDGC, International Parkinson's Disease Genomics Consortium.




Figure 1. Pooled relative risks and their 95% confidence intervals (95% CIs) for Parkinson's disease (PD) according to red hair color status (A; 1347 PD cases), *MC1R* p.R151C (rs1805007) (B; 8454 PD cases), and p.R160W (rs1805008) (C; 14934 PD cases) polymorphisms. HPFS = the health professionals follow-up study; NHS = the nurses' health study; PAGE = Parkinson's genes and environment; IPDGC = International Parkinson's Disease Genomics Consortium.

French-Canadian, UK, German, Greek, Dutch, and Spanish origins, overall representing white populations.^{5,7–11} PD diagnosis was generally ascertained by a neurologist or clinician according to the United Kingdom Parkinson's Disease Society Brain Bank Criteria.

Red hair was associated with significantly higher risk of PD, relative to black hair (pooled OR = 1.68; 95% CI: 1.07, 2.64; $P = 0.02$; PD case number = 1347^{5,7}) (Fig. 1A). When we further examined two *MC1R* red hair color alleles, we found that p.R151C variant was associated with marginally increased risk of PD (pooled OR = 1.101; 95% CI: 1.002, 1.210; $P = 0.046$; PD case number = 8454^{5,7–10}) (Fig. 1B). However, we did not find significant association between p.R160W and PD risk (pooled OR = 1.019; 95% CI: 0.956, 1.807; $P = 0.57$; PD case number = 14,934)^{7–11} (Fig. 1C). There was no strong evidence of publication bias based on the Begg and Egger tests ($P > 0.05$ for all).

Discussion

In this meta-analysis of six publications, totaling eight study cohorts,^{5,7–11} we found that red hair color was significantly associated with higher risk for PD. Red hair-associated *MC1R* variant p.R151C had a significant association with PD risk. Another red hair color variant, p.R160W, was not associated with PD risk.

The associations of red hair color and *MC1R* p.R151C with PD risk are consistent with our initial report.⁵ Skin/hair color is determined by relative production of brown–black eumelanin and yellow–red pheomelanin. Binding to its ligand α -melanocyte-stimulating hormone, the G protein-coupled *MC1R* induces synthesis of eumelanin through cAMP cascade.^{6,12} Loss-of-function *MC1R* variants including p.R151C facilitate pheomelanin formation and are associated with red hair/fair skin and increased risk of melanoma.^{6,12,13} *MC1R* is also involved in the regulation of other cellular functions independent of pigmentation.¹² Evidence supports a critical role of pheomelanin as a prooxidant in *MC1R* melanomagenesis,⁶ and involvement of red hair pigmentation in PD is supported by our original report⁵ and the present meta-analysis. Other studies have also implicated a potential role of general pigmentation in PD. For example, primary skin cultures from individuals with red hair color showed deregulation of genes involved in neurodegenerative diseases such as PD.¹⁴ A clinical study reported a correlation between light pigmentation phenotype and increased echogenicity of the substantia nigra.¹⁵ Furthermore, a GWA study identified melanogenesis as significant pathways for PD.¹⁶ However, it is not clear whether skin/hair pigmentation accounts all or in part for *MC1R* p.R151C-PD association.

Interestingly, despite limited knowledge about its biosynthetic pathway and its exact role in dopaminergic neuron degeneration, neuromelanin, the third melanin in humans in fact has a pheomelanin core and a eumelanin surface.¹⁷ This finding has led to a hypothesis that thinning eumelanin surface and exposing pheomelanin core may be responsible for the selective vulnerability of pigmented dopaminergic neurons in PD.¹⁸ Although early evidence supports expression of *MC1R* in brain,¹⁹ and *MC1R* has been proposed to be neuroprotective,⁸ it remains to be determined whether *MC1R* signaling plays any role in the synthesis and functions of neuromelanin and how neuromelanin is related to peripheral pigmentation, that is, skin/hair color.

MC1R p.R160W, another red hair-associated polymorphism that was associated with higher PD risk in one study with a Spanish population,⁸ did not show a significant positive association in our meta-analysis. One of the difficulties in ascertaining the association stems from the relatively low MAF and penetrance of *MC1R* in both PD and non-PD patients^{5,7–11} compared to other PD predisposing genes such as those of the family of *PARK* genes, though the frequency of *MC1R* mutations is comparable to those of melanoma cases.^{6,12} Furthermore, the frequency of minor alleles differs between populations,²⁰ and possible differential biological mechanisms and environmental interactions contributing to the mixed evidence for the association with PD should be clarified.

Although our original findings⁵ are generally supported by this meta-analysis, larger, prospective cohorts with different ethnic backgrounds are needed to verify the associations between hair color, p.R151C, and possibly other *MC1R* red hair variants and PD risk. In addition, laboratory studies would provide critical insight into the mechanistic roles of *MC1R* and pigmentation in dopaminergic neuron degeneration in PD.

Acknowledgments

The authors are supported by the Michael J. Fox Foundation (9908 to X. C.), National Institute of Health (1R21NS090246-01A1 to X. C., 5R21NS087235-02 to X. G.), and National Natural Science Foundation of China (81471293 to X.C.).

Author Contributions

X.C., D.F., and G.X. designed the study, acquired and analyzed data, and wrote the paper. M.A.S. provided critical comments on the study design and revised the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

References

- Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. *Neurology* 2011;76:2002–2009.
- Huang P, Yang XD, Chen SD, et al. The association between Parkinson's disease and melanoma: a systematic review and meta-analysis. *Transl Neurodegener* 2015; doi:10.1186/s40035-015-0044-y.
- Gao X, Simon KC, Han J, et al. Family history of melanoma and Parkinson disease risk. *Neurology* 2009;73:1286–1291.
- Kareus SA, Figueroa KP, Cannon-Albright LA, et al. Shared Predispositions of Parkinsonism and Cancer: a Population-Based Pedigree-Linked Study. *Arch Neurol* 2012;69:1572–1577.
- Gao X, Simon KC, Han J, et al. Genetic determinants of hair color and Parkinson's disease risk. *Ann Neurol* 2009;65:76–82.
- Roider EM, Fisher DE. Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans. *JAMA Dermatol* 2016;152:751–753.
- Dong J, Gao J, Nalls M, et al. Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. *Neurobiol Aging* 2014;35:1512.e5–1512.e10.
- Tell-Marti G, Puig-Butille JA, Potrony M, et al. The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. *Ann Neurol* 2015;77:889–894.
- Lubbe SJ, Escott-Price V, Brice A, et al. Is the MC1R variant p.R160W associated with Parkinson's? *Ann Neurol* 2016;79:159–161.
- Gan-Or Z, Mohsin N, Girard SL, et al. The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder. *Neurobiol Aging* 2016;43:180.e7–180.e13.
- Lorenzo-Betancor O, Wszolek ZK, Ross OA. Rare variants in MC1R/TUBB3 exon 1 are not associated with Parkinson's disease. *Ann Neurol* 2016;79:331.
- Wolf Horrell EM, Boulanger MC, D'Orazio JA. Melanocortin 1 Receptor: structure, Function, and Regulation. *Front Genet* 2016;7:95.
- Beaumont KA, Newton RA, Smit DJ, et al. Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. *Hum Mol Genet* 2005;14:2145–2154.
- Puig-Butille JA, Escámez MJ, Garcia-Garcia F, et al. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. *Oncotarget* 2014;5:1439–1451.
- Rumpf JJ, Schirmer M, Fricke C, et al. Light pigmentation phenotype is correlated with increased substantia nigra echogenicity. *Mov Disord* 2015;30:1848–1852.
- Edwards YJ, Beecham GW, Scott WK, et al. Identifying consensus disease pathways in Parkinson's disease using an integrative systems biology approach. *PLoS ONE* 2011;6:e16917.
- Bush WD, Garguilo J, Zucca FA, et al. The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. *Proc Natl Acad Sci U S A* 2006;103:14785–14789.
- Ito S. Encapsulation of a reactive core in neuromelanin. *Proc Natl Acad Sci U S A* 2006;103:14647–14648.
- Xia Y, Wikberg JE, Chhajlani V. Expression of melanocortin 1 receptor in periaqueductal gray matter. *NeuroReport* 1995;6:2193–2196.
- Gerstenblith MR, Goldstein AM, Fargnoli MC, et al. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. *Hum Mutat* 2007;28:495–505.